On Wednesday, March 10 and Thursday, March 11, the FDA is convening an Advisory Committee meeting on the clinical trial design for long acting beta-2 adrenergic agonists (LABA's).
Bob Lanier, M.D., executive medical director of the American College of Allergy, Asthma and Immunology (ACAAI) will address the committee in support of the safety of LABA's when used as recommended and is available for interviews.
Dr. Lanier is a practing allergist and past president of ACAAI and is recipeint of the ACAAI Distinguished Fellow Award. He also is a past president of the Association of Certified Allergists and the Tarrant County Medical Society. He serves on the Emerging Medical Societies taskforce and the Board of Directors for the World Allergy Association and travels extensively in that capacity.
Dr. Lanier is a clinical professor at the University of North Texas Health Science Center, Texas College of Osteopathic Medicine. He has authored over 60 original contributions to the medical literature in peer reviewed journals, has written two textbook chapters in allergy and is active in the cutting edge of respiratory research through his firm North Texas Institute for Clinical Trials, being best known for his work on monoclonal anti-IgE. He has given over 100 presentations for Medical grand rounds in universities in this country, Europe, Asia, Australia, and South America in the last three years and is widely known for his dynamic, technologically advanced, and entertaining style.
Research confirms no association between SARS-CoV-2 and childhood asthma diagnoses